Nobivac^® Parvo-C Questions and Answers

For active immunisation of dogs to prevent mortality, clinical signs and viral excretion following canine parvovirus infection.

The onset of immunity is 1 week following vaccination.

Where earlier protection is required a first dose may be given to puppies from 4 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose at 10 weeks of age or older is generally recommended.

The duration of immunity is expected to last at least 3 years.

It is recommended that dogs are revaccinated against canine parvovirus every 3 years but where earlier protection is required a first dose may be given to puppies from 4 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose at 10 weeks of age or older is generally recommended.

Yes, it can be used in pregnant bitches which have previously been vaccinated with the CPV (strain 154) antigens included in the Nobivac vaccine series.

We do not hold specific data regarding use during lactation and therefore cannot recommend this use during this period.

Nobivac Parvo-C requires storage in a refrigerator between 2 ^oC and 8 ^oC. Do not freeze. Protect from light.

Care should be taken to avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use - in hot summer conditions vaccine potency can be severely reduced within a few hours.

There are no breed-specific contraindications for Nobivac Parvo-C.

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccines of the Nobivac series for subcutaneous administration against canine leptospirosis caused by all or some of the following serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang.

Safety and efficacy data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the inactivated vaccine of the Nobivac range against Bordetella bronchiseptica.

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with Nobivac^® Rabies.

In the situation that concurrent vaccination with Nobivac Parvo-C, Nobivac Lepto 2 and Nobivac Rabies is desired it is advisable to mix Nobivac Parvo-C either with Nobivac^® Lepto 2 or Nobivac Rabies and to administer as 2 separate injections.

Where earlier protection is required a first dose may be given to puppies from 4 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose at 10 weeks of age or older is generally recommended.

A single injection should establish active immunity to disease caused by canine parvovirus infection in dogs of 10 weeks of age or older.